Real‐world use of glucagon‐like peptide‐1 receptor agonists in youth with type 2 diabetes is associated with short‐term improvements in HbA1c

Ähnliche Einträge

• Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
  von: Masashi Hasebe, et al.
  Veröffentlicht: (2025)
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
  von: David C. Klonoff, et al.
  Veröffentlicht: (2024)
• Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
  von: Darren Lau, et al.
  Veröffentlicht: (2024)
• Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
  von: Jason M. Samuels, et al.
  Veröffentlicht: (2024)
• Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist
  von: Jessica Van Laren, et al.
  Veröffentlicht: (2026)